Shots:
PharmaCyte initiated the 1st phase of the study which evaluates the microcatheter-based delivery of CypCaps inj. (100) in the pancreatic arterial system of Yorkshire pigs (n=2, 90 Lbs.) using its Cell-in-a-Box technology. Fluoroscopy will be used to study the vascular anatomy, treatment site suitability & acute deployment characteristics
The results of the 1st phase study will aid the final protocol generation for the 2nd phase study that will be presented to the US FDA for review & guidance
The company is performing these 2 phased studies to lift the clinical hold on the P-IIb trial evaluating CypCaps under its Cell-in-a-Box technology to treat LAPC. Both the studies are being conducted by CBSET
Ref: Bussinesswire | Image: PharmaCyte
